Search
Search

Ethical Guidance for Selecting Clinical Trials to Receive Limited Space in an Immunotherapy Production Facility

Name / volume / issue

65965

Page number

58-70

Primary author

Nancy S. Jecker, Aaron G. Wightman, Abby R. Rosenberg & Douglas S. Diekema

Tag(s): Journal article

Abstract

Our aims are to (1) set forth a multiprinciple system for selecting among clinical trials competing for limited space in an immunotherapy production facility that supplies products under investigation by scientific investigators; (2) defend this system by appealing to justice principles; and (3) illustrate our proposal by showing how it might be implemented. Our overarching aim is to assist manufacturers of immunotherapeutic products and other potentially breakthrough experimental therapies with the ethical task of prioritizing requests from scientific investigators when production capacity is limited.

Full text

Related posts

Harm Reduction: A Weak Justification For Obesity Drugs And Surgery

In the United States, nearly 41 percent  of the population is obese. In 2023, the American Academy of Pediatrics approved bariatric surgery and pharmaceuticals as an approach to pediatric obesity and revised recommendations, encouraging pediatricians to refer patients for obesity interventions including drugs and surgery sooner. The recommendations were part of a comprehensive plan that […]

The Code Blue Pharmacist 

A patient coded at my hospital without having clear guidelines about what he wanted for treatment plan. It left the hospital staff in a flurry to receive verbal consent from his wife in order to treat him. Bedside ethics are important in cases where decisions about patient care need to be made rapidly. These types […]

AstaZeneca’s Vaccine Ethical Problem

Brian M. Cummings, MD and John J. Paris, SJ, PhD In The New York Times, almost overlooked amidst multiple articles on Covid-19 published that day, we found a challenging essay by Max Fisher entitled, “Europe’s Vaccine Ethics Call:  Do No Harm and Let More Die”?  Fisher inquires whether clinical bioethics should accept the decision of Germany to suspend the […]

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Privacy Policy. By closing this message, you are consenting to our use of cookies.

close